Cargando…
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study
BACKGROUND: There has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs). METHODS: In this single-arm phase II study, patients with cancer with grade ≥2 irP received oral prednisolone (1 mg/kg/day), tapered over 6 weeks. The...
Autores principales: | Karayama, Masato, Inui, Naoki, Inoue, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Ikeda, Masaki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Funayama, Satoshi, Ichikawa, Shintaro, Goshima, Satoshi, Suda, Takafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387737/ https://www.ncbi.nlm.nih.gov/pubmed/37500182 http://dx.doi.org/10.1136/jitc-2023-007056 |
Ejemplares similares
-
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer
por: Karayama, Masato, et al.
Publicado: (2021) -
Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy: The Authors' Reply
por: Karayama, Masato, et al.
Publicado: (2019) -
Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians
por: Koyauchi, Takafumi, et al.
Publicado: (2022) -
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020) -
Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non–Small Cell Lung Cancer After Nivolumab Therapy
por: Karayama, Masato, et al.
Publicado: (2022)